ES2194437T3 - Procedimiento para producir microparticulas absorbibles. - Google Patents

Procedimiento para producir microparticulas absorbibles.

Info

Publication number
ES2194437T3
ES2194437T3 ES99902793T ES99902793T ES2194437T3 ES 2194437 T3 ES2194437 T3 ES 2194437T3 ES 99902793 T ES99902793 T ES 99902793T ES 99902793 T ES99902793 T ES 99902793T ES 2194437 T3 ES2194437 T3 ES 2194437T3
Authority
ES
Spain
Prior art keywords
peptide
absorbable
hormone
polymer
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99902793T
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kinerton Ltd
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of ES2194437T3 publication Critical patent/ES2194437T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para preparar una micropartícula o micropartículas unida(s) y confinada(s), en el que la micropartícula o las micropartículas unidas y confinadas comprenden micropartícula o micropartículas unidas y un polímero de confinamiento absorbible en el que: la micropartícula o micropartículas unidas comprenden un núcleo polímero heterocatenario absorbible y uno o más péptidos, una o más proteínas o una de sus combinaciones, inmovilizados sobre dicho núcleo polímero heterocatenario absorbible en el que cada péptido se selecciona independientemente del péptido liberador de la hormona del crecimiento (GHRP), hormona liberadora de la hormona luteinizante (LHRH), somatostatina, bombesina, péptido liberador de gastrina (GRP), calcitonina, bradiquinina, galamina, hormona estimuladora de melanocitos (MSH), factor de liberación de la hormona del crecimiento (GRF), amilina, taquiquininas, secretina, hormona de paratiroides (PTH), encefalina, endotelina, péptido liberador del gen de calcitonina (CGRP), neuromedinas, proteína relacionada con la hormona de paratiroides (PTHrP), glucagón, neurotensina, hormona adrenocorticotrófica (ACTH), péptido YY (PYY), péptido liberador de glucagón (GLP), péptido intestinal vasoactivo (VIP), péptido activador de adenilato-ciclasa de la glándula pituitaria (PACAP), motilina, sustancia P, neuropéptido Y (NPY), TSH y sus análogos y fragmentos o una de sus sales farmacéuticamente aceptables; y en el que cada proteína se selecciona independientemente de hormona del crecimiento, eritropoyetina, factor estimulador de colonias de granulocitos, factor estimulador de colonias de macrógafos-granulocitos e interferones; dicho procedimiento que comprende las etapas de: obtener una dispersión, en el que la dispersión comprende micropartículas unidas sólidas en una solución del polímero de confinamiento absorbible, por homogeneización y simultáneamente por dispersión de dichas micropartículas unidas sólidas en la solución de un polímero de confinamiento absorbible; y nebulizar dicha dispersión a través de una sonda de nebulización, en el que dicha sonda tiene un intervalo operativo de frecuencia ultrasónica de 12 kHz a 36 kHz, en un medio, en el que el medio es un no disolvente de dicho polímero de confinamiento absorbible, a un caudal de aproximadamente 1 ml/minuto a 15 ml/min.
ES99902793T 1998-01-29 1999-01-25 Procedimiento para producir microparticulas absorbibles. Expired - Lifetime ES2194437T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE980054 1998-01-29

Publications (1)

Publication Number Publication Date
ES2194437T3 true ES2194437T3 (es) 2003-11-16

Family

ID=11041696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99902793T Expired - Lifetime ES2194437T3 (es) 1998-01-29 1999-01-25 Procedimiento para producir microparticulas absorbibles.

Country Status (17)

Country Link
US (1) US6555156B1 (es)
EP (1) EP1051194B9 (es)
JP (1) JP2002501907A (es)
CN (1) CN1289255A (es)
AR (1) AR014069A1 (es)
AT (1) ATE240121T1 (es)
AU (1) AU740493B2 (es)
CA (1) CA2318513A1 (es)
DE (1) DE69907870T2 (es)
DK (1) DK1051194T3 (es)
ES (1) ES2194437T3 (es)
HU (1) HUP0102373A2 (es)
IL (1) IL137349A0 (es)
NO (1) NO20003804L (es)
PL (1) PL342135A1 (es)
PT (1) PT1051194E (es)
WO (1) WO1999038535A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
IES990700A2 (en) 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EP1581245A2 (en) 2002-12-17 2005-10-05 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
TW200538148A (en) * 2004-01-13 2005-12-01 Vasogenix Pharmaceuticals Inc Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
US7578951B2 (en) * 2004-01-27 2009-08-25 Hewlett-Packard Development Company, L.P. Method of making microcapsules utilizing a fluid ejector
US20060084628A1 (en) 2004-10-19 2006-04-20 Achillion Pharmaceuticals Combination therapy for treating viral infections
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
JP5649825B2 (ja) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化させたｐ５３ペプチドおよびその使用法
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2010009291A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8968787B2 (en) * 2010-05-24 2015-03-03 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
CN108570097A (zh) 2010-08-13 2018-09-25 爱勒让治疗公司 拟肽大环化合物
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
SG11201404648PA (en) 2012-02-15 2014-09-26 Aileron Therapeutics Inc Peptidomimetic macrocycles
EP2914256B1 (en) 2012-11-01 2019-07-31 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
JP2018532785A (ja) 2015-11-06 2018-11-08 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． 生体適合性かつ生分解性のポリマー、ナノ担体および薬物を含む組成物ならびにその作製および使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
EP0565618A4 (en) * 1991-01-03 1994-06-29 Alkermes Inc Stabilization of proteins by cationic biopolymers
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0712421A1 (en) * 1993-07-23 1996-05-22 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides

Also Published As

Publication number Publication date
PL342135A1 (en) 2001-05-21
DE69907870T2 (de) 2004-03-04
HUP0102373A2 (hu) 2001-10-28
PT1051194E (pt) 2003-09-30
NO20003804D0 (no) 2000-07-25
EP1051194A1 (en) 2000-11-15
EP1051194B1 (en) 2003-05-14
AU740493B2 (en) 2001-11-08
JP2002501907A (ja) 2002-01-22
EP1051194B9 (en) 2003-11-05
WO1999038535A1 (en) 1999-08-05
AU2296699A (en) 1999-08-16
CA2318513A1 (en) 1999-08-05
IL137349A0 (en) 2001-07-24
NO20003804L (no) 2000-09-20
DE69907870D1 (de) 2003-06-18
AR014069A1 (es) 2001-01-31
US6555156B1 (en) 2003-04-29
CN1289255A (zh) 2001-03-28
ATE240121T1 (de) 2003-05-15
DK1051194T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
ES2194437T3 (es) Procedimiento para producir microparticulas absorbibles.
AR014510A1 (es) Microparticulas absorbibles y procedimiento para su preparacion.
RU2000126755A (ru) Фармацевтические композиции, предназначенные для пролонгированного высвобождения пептидов, и способ их приготовления
CA2324901A1 (fr) Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
RU99124209A (ru) Композиции пролонгированного высвобождения и способ их получения
RU2000122622A (ru) Абсорбируемые микрочастицы
RO117259B1 (ro) Derivaţi peptidici, terapeutici
JP2019103847A5 (ja) 吸入器
NO995558D0 (no) Terapeutisk middel for cachexi
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
WO2005044985A3 (en) Delivery of polymer conjugates of therapeutic peptides and proteins via coated microporjections
RU2009103210A (ru) Фармацевтические композиции для доставки пептидов с замедленным высвобождением
NO993341L (no) Analoger av paratyroidhormon
TR201903610T4 (tr) Alfa-melanosit uyarici hormonlarin peptid analoglari.
AR052884A1 (es) Formulaciones peptidicas terapeuticas con estbilidad mejorada
Chatzistamou et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone
RU96104340A (ru) Производная пептида, димерная производная пептида и способ лечения заболевания пациента
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2289775T3 (es) Composiciones de ligando/peptido litico y metodos de uso.
EP1098660B1 (en) Encapsulation of water soluble peptides
Toogood et al. Ghrelin, not just another growth hormone secretagogue.
ATE359059T1 (de) Zubereitungen zur intranasalen applikation ausgewählter, von aminosäuren abgeleiteter cgrp- antagonisten
IL145403A0 (en) Fragments of virus protein 2 or 3 of the polyoma virus, use for transporting active ingredients
Zabel et al. Immunocytochemical characterization of two thyroid medullary carcinoma cell lines in vitro